Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV

dc.contributor.authorDuart Castells, Leticia
dc.contributor.authorLópez Arnau, Raúl
dc.contributor.authorBuenrostro Jáuregui, Mario
dc.contributor.authorMuñoz-Villegas, P.
dc.contributor.authorValverde, Olga
dc.contributor.authorCamarasa García, Jordi
dc.contributor.authorPubill Sánchez, David
dc.contributor.authorEscubedo Rafa, Elena
dc.date.accessioned2020-01-20T12:19:53Z
dc.date.available2020-01-20T12:19:53Z
dc.date.issued2018-10-12
dc.date.updated2020-01-20T12:19:53Z
dc.description.abstract3,4-methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with cocaine-like properties. In a previous work, we exposed adolescent mice to MDPV, finding sensitization to cocaine effects, and a higher vulnerability to cocaine abuse in adulthood. Here we sought to determine if such MDPV schedule induces additional behavioral-neuronal changes that could explain such results. After MDPV treatment (1.5 mg·kg-1, twice daily, 7 days), mice were behaviorally tested. Also, we investigated protein changes in various brain regions MDPV induced aggressiveness and anxiety, but also contributed to a faster habituation to the open field. This feature co-occurred with an induction of ΔFosB in the orbitofrontal cortex that was higher than its expression in the ventral striatum. Early after treatment, D2R:D1R ratio pointed to a preponderance of D1R but, upon withdrawal, the ratio recovered. Increased expression of Arc, CDK5 and TH, and decrease in DAT protein levels persisted longer after withdrawal, pointing to a neuroplastic lasting effect similar to that involved in cocaine addiction. The implication of the hyperdopaminergic condition in the MDPV-induced aggressiveness cannot be ruled out. We also found an initial oxidative effect of MDPV, without glial activation. Moreover, although initially the dopaminergic signal induced by MDPV resulted in increased ΔFosB, we did not observe any change in NFκB or GluA2 expression. Finally, the changes observed after MDPV treatment could not be explained according to the autoregulatory loop between ΔFosB and the epigenetic repressor G9a described for cocaine. This provides new knowledge about the neuroadaptive changes involved in the vulnerability to psychostimulant addiction.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec682923
dc.identifier.issn0028-3908
dc.identifier.urihttps://hdl.handle.net/2445/148191
dc.language.isoeng
dc.publisherElsevier Ltd
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.neuropharm.2018.10.005
dc.relation.ispartofNeuropharmacology, 2018, vol. 144, p. 271-281
dc.relation.urihttps://doi.org/10.1016/j.neuropharm.2018.10.005
dc.rightscc-by-nc-nd (c) Elsevier Ltd, 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationCocaïna
dc.subject.classificationDopamina
dc.subject.classificationAmfetamines
dc.subject.classificationRatolins
dc.subject.classificationDrogues de disseny
dc.subject.otherCocaine
dc.subject.otherDopamine
dc.subject.otherAmphetamines
dc.subject.otherMice
dc.subject.otherDesigner drugs
dc.titleNeuroadaptive changes and behavioral effects after a sensitization regime of MDPV
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
682923.pdf
Mida:
774.31 KB
Format:
Adobe Portable Document Format